Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMode Ltd.INMD · Entity 5052 | Director · Chief Executive Officer | March 18, 2026 | March 18, 2026 |
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Director | December 06, 2023 | December 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMode Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.01 per ordinary shareSEC Table I · non-derivative | Direct | 4,299,226 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,299,226 |
Xenetic Biosciences, Inc.
Report date December 06, 2023 · Filed December 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.29 · Expires 2033-12-06 | Direct | 2,500 |
Reported balance
After 2023-12-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-06 · Grant · Acquired 2,500 · Balance 2,500 F1: The Options vest 100% on the twelve-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest 100% on the twelve-month anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2023 Filed Dec 18, 2023 22:18 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001683168-23-008917 · ownership.xml · derivative · entry 1 Mizrahy Moshe · CIK 0001803068 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-12-06 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.